Mohit Gupta, MD
Internal Medicine · Trenton, MINPI 1851522627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $321 and has fallen 80.3% since, to $63 in 2025.
Across 62 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$130
- Lilly USA, LLC$115
- AstraZeneca$98
- AbbVie$80
- Nestle Healthcare Nutrition Inc.$76
- Amarin Pharma, Inc.$74
- plus $469 from 15 others
What the payments were for
- Food & beverage$1,041100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $130 |
| Lilly USA, LLC | 8 | $115 |
| AstraZeneca | 6 | $98 |
| AbbVie | 5 | $80 |
| Nestle Healthcare Nutrition Inc. | 4 | $76 |
| Amarin Pharma, Inc. | 5 | $74 |
| Neurocrine Biosciences, Inc. | 4 | $71 |
| Merck | 4 | $62 |
| Pfizer | 3 | $56 |
| Lundbeck LLC | 2 | $50 |
| Exact Sciences | 2 | $32 |
| Novartis | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Amgen | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$1,041 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $62,061 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $60,600 |
| JanuviaSitagliptin Phosphate | 30 | $24,519 |
| MounjaroTirzepatide | 18 | $21,441 |
| JardianceEmpagliflozin | 18 | $11,511 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $9,194 |
| EntrestoSacubitril/Valsartan | 13 | $8,710 |
| TrintellixVortioxetine Hydrobromide | 13 | $8,003 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $6,487 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,904 |
| MyrbetriqMirabegron | 11 | $4,669 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 285 | $4,460 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 114 | $4,450 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,060 |
| Varenicline Tartrate | 13 | $2,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $130 | $66,50598 claims |
| PfizerEliquis | $56 | $62,06165 claims |
| MerckJanuvia | $62 | $24,51930 claims |
| Lilly USA, LLCMounjaro | $115 | $21,44118 claims |
| Boehringer IngelheimJardiance | $20 | $11,51118 claims |
| NovartisEntresto | $32 | $8,71013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Trenton
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.